Listen
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement only in the indications having previously received a favourable opinion for inclusion in the list of covered drugs for inpatients approved for use following previous assessments by the Committee.
No clinical added value of this new form of KEYTRUDA 25 mg/ml concentrate for solution for infusion in packs containing two 4-mL glass vials compared to the pembrolizumab form already available.
Clinical Benefit
| Unspecified |
The clinical benefit of KEYTRUDA (pembrolizumab) is identical to the clinical benefit levels already granted by the Committee following its previous assessments. |
| Insufficient |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
